CLIENT ALERT / US POLICY
Fourth Circuit Stays Preliminary Injunction of Executive Orders Related to DEI Programs
March 18, 2025
Read time: 3 min
On March 14, 2025, the US Court of Appeals for the Fourth Circuit issued a stay on the US District Court for the District of Maryland’s nationwide preliminary injunction of US President Donald Trump’s executive orders (EOs) that target diversity, equity, and inclusion (DEI) programs – namely, EO Nos. 14151 and 14173 – which allows the government to implement and enforce the EOs while litigation continues.
In granting the stay, each member of the three-judge panel issued a concurring opinion explaining their reasoning. Chief Judge Albert Diaz and Judge Pamela Harris agreed that the government showed a sufficient likelihood that it will succeed in demonstrating that the EOs are not unconstitutional, in part because the EOs are limited in scope. For example, the EOs do not state that all efforts to advance DEI are illegal; rather, the “certification” and “enforcement threat” provisions apply only to conduct that violates existing anti-discrimination laws. Additionally, the “termination” provision directs the termination of grants based on the nature of the grant-funded activity, not the grantee’s external speech or activities, which both judges noted might implicate First and Fifth Amendment concerns. Judge Diaz further hinted that the anti-DEI EOs may be unconstitutionally vague as they lack clear definitions of what types of programs the Trump administration seeks to eliminate. Judge Allison Jones Rushing considered the injunction overbroad and believes the government is likely to demonstrate that the anti-DEI EOs are constitutional directives by the president to his officers. Judge Rushing also noted that the case may not be ripe for review because there is no specific agency action being challenged.
The ruling is not a final decision on the legality of the EOs. It merely allows the government to administer the policy while litigation continues. The Fourth Circuit will retain jurisdiction to hear the case on the merits and has agreed to an expedited briefing.
A final ruling on the merits is expected in the next three to six months. In the meantime, employers should keep working with legal counsel to proactively audit their DEI policies to ensure compliance with existing laws while maintaining alignment with company values.

Unclaimed Property Laws and the Health Industry: Square Peg, Round Hole
ARTICLE
Unclaimed Property Laws and the Health Industry: Square Peg, Round Hole
Mar 18, 2025
Read time: 2 min
The healthcare industry has recently become the target of increased scrutiny from multistate unclaimed property audits, likely due to the high volume of mergers, acquisitions, and private equity deals. These audits have shed light on the many complexities and challenges within the sector. Healthcare industry holders are often pressured by state auditors and administrators to fit a square peg in a round hole – something both they and their advocates should continue to actively push back against.
Identifying whether any “property” needs to be reported can be a significant challenge in an industry where a single patient transaction involves multiple parties and is governed by intricate business agreements, which are continuously updated and managed. Unclaimed property audits, however, are typically conducted with a narrow focus on a single holder and use standardized document requests designed for a broad range of businesses. This approach often leads to unrealistic expectations for record retention and management, which rarely align with the specific laws and practices of the healthcare industry.

Breaking Down the New No Surprises Act FAQs Post-TMA III
ARTICLE / CLIENT ALERT
Breaking Down the New No Surprises Act FAQs Post-TMA III
March 17, 2025
Read time: 14 min
UPDATE: On May 30, 2025, the Fifth Circuit granted the TMA III plaintiffs’ petition for rehearing en banc, which was previously filed on December 16, 2024. Of note, the Fifth Circuit’s mandate has not yet been issued, so as a technical matter, it never changed the District Court’s holding in TMA III. Accordingly, pending the results of the rehearing en banc, which could take approximately one year, there should be no material changes to the IDR process. CMS’s prior guidance, ACA & CAA FAQ Pt 69, which we wrote about below, also contemplated the potential for the en banc hearing and provides that pending the Fifth Circuit’s mandate being issued, consistent with FAQs Part 62 and the District Court’s ruling, plans and issuers can continue to rely on any QPAs that have already been calculated using a good faith, reasonable interpretation of the 2023 methodology.
On January 14, 2025, the US Departments of Labor, Health and Human Services (HHS), and the Treasury (collectively, the Departments), along with the Office of Personnel Management (OPM), jointly issued Part 69 of a series of frequently asked questions (FAQs) designed to help stakeholders understand and adhere to the federal No Surprises Act (NSA). This installment of the FAQs discusses how health plans and issuers should calculate the qualifying payment amount (QPA) and provides updates to disclosure and patient cost-sharing requirements following rulings by the US District Court for the Eastern District of Texas and the US Court of Appeals for the Fifth Circuit in Texas Medical Association, et al. v. United States Department of Health and Human Services, et al. (together, the TMA III decisions).
Background: The Long History of the NSA
The NSA was enacted under the first Trump administration as part of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260). The Departments and OPM jointly implemented provisions of the NSA through the issuance of two interim final rules (IFRs) in July 2021 and October 2021.
The NSA prohibits out-of-network (OON) providers from balance billing patients for certain services furnished at an OON facility (in the case of emergency services) or in-network facility (in the case of non-emergency services provided by OON providers). The NSA protects patients from receiving these “surprise” bills, effectively limiting patient responsibility for some services to no more than the patients’ in-network cost-sharing amounts. (The NSA includes separate considerations related to air ambulance providers, which we do not address in this article.)
Per the NSA and as further implemented in the October 2021 IFR, plans and issuers are required to determine whether claims for items or services submitted by an OON provider or facility and subject to the NSA are covered under the plan or coverage and must send an initial payment or notice of denial of payment to the OON provider or facility no later than 30 calendar days after the provider or facility submitted the claim to the plan or issuer.
To the extent the claim is covered, the NSA also sets forth a methodology by which plans or issuers must calculate the OON rate for OON providers or facilities that rendered items or services subject to the NSA. Plans and issuers must pay the provider or facility an amount determined by an applicable All-Payer Model Agreement, and if none exists, an amount determined by applicable state law. If state law does not set forth a mechanism by which the OON rate should be determined, the plan or issuer may negotiate the rate with the provider or facility through an “open negotiation” process, which lasts 30 days.
If the parties are unable to agree to an OON rate by the expiration of the open negotiation period, either party may initiate a dispute under the federal independent dispute resolution (IDR) process established by the NSA. The IDR process involves several steps:
- The disputing parties must agree on and select a third-party entity (referred to as a certified IDR entity) to oversee the process.
- Each party must then submit payment offers to the IDR entity.
- The IDR entity evaluates the payment offers and determines each party’s payment responsibility. The NSA requires that the IDR entity consider, among other factors, the QPA, defined as the median of the contracted rates that a plan or issuer recognizes for the same or similar service by a provider in the same or similar specialty in the same geographic area as the service at issue.
- Once the IDR entity makes a payment determination, the plan or issuer must make the payment to the OON provider or facility within 30 calendar days.
In August 2022, the Departments issued final rules implementing provisions regarding certain disclosure requirements for plans and issuers (discussed further below) and modifying certain requirements pertaining to how IDR entities can take into account the QPA in determining the OON rate through the IDR process.
In theory, the IDR process is straightforward. However, the NSA and the IDR process, including the significance of the QPA in determining the OON rate, have been the subject of consistent litigation and operational issues, suggesting that in practice, providers and health plans continue to encounter implementation challenges.
History of TMA Litigation
A string of litigation continues to shape the NSA and the related IDR process, which originated with a suit filed by the Texas Medical Association (TMA) against HHS in October 2021. In Texas Medical Association v. United States Department of Health and Human Services, et al. (TMA I), the district court vacated the Departments’ IFR requiring IDR entities to use a rebuttable presumption in favor of the QPA. The court held that the presumption conflicted with the NSA’s plain meaning, which lists a set of factors for consideration when determining the appropriate OON rate, only one of which is the QPA.
After the TMA I decision, the Departments issued the August 2022 final rules, which specified elements that IDR entities must consider in resolving OON payment disputes, including the extent to which the QPA should be taken into account. The August 2022 rules required that IDR entities:
- First consider the QPA for the same or similar service.
- Limit factors to information provided by the disputing party.
- Document non-QPA factors relied upon in making a payment determination.
However, TMA challenged this rule in Texas Medical Association v. United States Department of Health and Human Services, et al. (TMA II), which the Fifth Circuit eventually vacated in TMA III. The Fifth Circuit stated that the Departments exceeded their authority by instructing IDR entities to prioritize one factor over others.
In August 2023, the district court issued a decision in TMA III, overturning key parts of the method set forth by the Departments to calculate the QPA. Following this ruling, the Departments have exercised their discretion in enforcing how QPAs are calculated, leading to uncertainty for plans and issuers as well as providers and facilities. The federal government appealed part of this decision, and on October 30, 2024, the Fifth Circuit issued a ruling on the TMA III case, partially reversing the district court’s decision, while upholding other parts.
The district court’s TMA III opinion found that the Departments’ methodology for calculating the QPA did not comply with the NSA. This noncompliance was due to:
- The inclusion of “ghost rates” (i.e., contacted rates for services not actually provided by the contracting provider during the contract period).
- The exclusion of risk-based incentive payments.
- The allowance for self-insured plans administered by a third-party administrator to use other plans administered by the third-party administrator to calculate QPAs.
The district court also found that rules related to the timing and deadline for payment of OON claims subject to the NSA did not comply with the statute, because they started the 30-day payment clock on the date the plan or issuer received sufficient information to determine whether the submitted claim was a “clean claim,” rather than the date the provider or facility transmitted a “claim.”
Reversing the district court’s decision in part, the Fifth Circuit held that single-case arrangements will no longer be included in QPA calculations. The Fifth Circuit also reversed the district court’s decision that non-fee payments, such as quality bonuses and other incentives, must be included in QPA calculations. Regarding the timing of OON payments subject to the NSA, the Fifth Circuit affirmed the district court’s decision that starting the 30-day payment clock upon receipt of a “clean claim” conflicts with the text of the NSA. As decided by the district court, the 30-day prompt payment clock for NSA-eligible claims will begin on the date the provider transmits the bill, not when the plan or issuer receives the information necessary to determine whether the claim is a “clean claim.”
Regarding the QPA calculation, the Fifth Circuit reversed the district court’s decision to exclude from QPA calculations any contracts for items or services that contracting providers did not actually furnish under said contract during the designated plan year. Contracted rates can now be included in QPA calculations regardless of whether the provider actually furnished those services. However, the Fifth Circuit reiterated the statutory requirement that QPAs be calculated using contracts for the “same or similar item or service that is provided in the same or similar specialty.” This implies that “ghost rates” (e.g., anesthesia rates included in a primary care physician’s contract) must be excluded from QPA calculations.[1]
Following the TMA III decisions, the Departments stated on the Centers for Medicare and Medicaid Services’ NSA webpage in October 2024 that they were reviewing the Fifth Circuit’s decision and intended to “issue further enforcement guidance in the near future.”
New Guidance Issued for QPA Calculations Post-TMA III Decisions
In the wake of the TMA III decisions, the Departments issued the FAQs addressing implementation of certain provisions of the NSA and responding to questions from stakeholders. Under the FAQs, the Departments and OPM will require health plans and issuers to calculate QPAs using a “good faith, reasonable interpretation of the applicable statutes and regulations that remain in effect following the decisions of both the Fifth Circuit and the district court in TMA III (the 2024 methodology)” once the Fifth Circuit issues its final order. Under Federal Rule of Appellate Procedure 41, a court of appeals’ mandate usually issues seven days after the deadline for rehearing petitions, unless a petition is filed. In this case, the Fifth Circuit withheld the mandate after the plaintiffs in TMA III filed a petition for rehearing en banc. Until the mandate is issued, the district court’s judgment continues to bind the Departments.
The Departments and OPM acknowledged the challenges of recalculating QPAs because of the Fifth Circuit’s decision and recognized the time and resources required for this task. Therefore, the Departments opted to prolong the existing period of “enforcement discretion” for any health plan or issuer that calculates a QPA using either the 2021 methodology (based on the IFRs and guidance issued in July 2021) or the 2023 methodology (based on the statutes and regulations that remained in effect after the district court’s decision in TMA III). Both methodologies can be used for items and services furnished before August 1, 2025, as long as they are based on a good faith, reasonable interpretation.
Once the mandate is issued, the Departments and OPM will also use their discretion to enforce the NSA for any health plan, issuer, or party involved in a payment dispute that uses a QPA calculated with the 2023 methodology for services provided before August 1, 2025. This enforcement discretion applies to patient cost-sharing, required disclosures with initial payments or notices of denials, and submissions under the IDR process. Similarly, HHS will exercise enforcement discretion for providers and facilities that bill patients based on a QPA calculated with the 2021 or 2023 methodology for services provided before August 1, 2025. Thus, the FAQs clarify that the enforcement discretion extends to providers in addition to health plans.
The FAQs encourage states, which primarily enforce the NSA, to adopt a similar approach, including that states will be considered compliant if they follow this approach. The Departments and OPM will reassess whether additional enforcement relief time is needed as health plans and issuers work to comply with the applicable laws and regulations following the TMA III decisions.
The new FAQs essentially preserve the existing circumstances, as the enforcement discretion has been operative since fall 2023 after the district court’s TMA III decision. Alongside the enforcement guidance, the Departments and OPM offer further clarifications regarding the existing QPA disclosure requirements and patient cost-sharing obligations.
Disclosure Requirements
In line with previous guidance, which remains unaffected by the TMA III decisions, health plans and issuers must continue to disclose information about the QPA. The QPA is used to determine the “recognized amount” for cost-sharing under the NSA. This recognized amount is calculated using the All-Payer Model Agreement, specified state law, or the lesser of the billed charge or QPA. A health plan or issuer may certify that a QPA was determined in compliance with applicable rules by using a good faith, reasonable interpretation of the statutes and regulations that remain in effect following the TMA III decisions.
The FAQs address questions regarding the 30-day notice and IDR process discussed earlier, and how the timing is affected when a plan sends the initial payment or denial notice electronically but provides the required disclosures in paper form. This can result in the provider receiving the payment or denial notice earlier than the disclosures. The Departments and OPM clarify that a plan must transmit the required disclosures on or near the date that it sends the initial payment or notice of denial of payment, and must ensure that both the initial payment or notice of denial of payment and the required disclosures are sent no later than 30 calendar days after the plan receives the information necessary to decide a claim for payment for the services billed by the provider.
The Departments and OPM also state in the FAQs that they recognize that sometimes providers and facilities receive required disclosures days after receiving the initial payment or denial notice. Since the 30-business-day period to start open negotiation begins when the payment or denial notice is received, this delay can shorten the time available to review the disclosures. If the disclosures are sent in paper form and arrive later than the electronic payment or denial notice, the 30-business-day period to start negotiations will be considered to begin once both the payment or denial notice and the disclosures are received. Providers can still choose to start negotiations after receiving the payment or denial notice but before receiving the disclosures.
Patient Cost-Sharing
The Departments and OPM reiterate in the FAQs that patient cost-sharing rules under the NSA and the July 2021 IFR for OON emergency services and certain non-emergency services are based on the “recognized amount.” According to the Departments and OPM, some health plans have been found to increase cost-sharing amounts after an IDR payment determination, which is not allowed. Once an IDR entity makes a payment determination, plans cannot recalculate or increase the cost-sharing amount if it exceeds the permitted amount. The rules ensure that disputes between providers and payers do not affect the cost-sharing amount for individuals. Nonparticipating providers cannot bill individuals more than the allowed cost-sharing amount. Any payment owed to nonparticipating providers after an IDR determination must be paid in full without reducing the amount based on prohibited cost-sharing increases.
Conclusion/Key Takeaways
As stated earlier, Part 69 of the FAQs extends the status quo of enforcement discretion around the calculation of the QPA. Any new regulations related to the QPA calculation will need to be drafted under the Trump administration, although the timing for issuing such regulations is unclear. If the Trump administration decides to draft new QPA regulations, it could make additional changes to the QPA methodology beyond those that have been the subject of litigation. While the courts have provided direction on what is permissible under the NSA and what aspects of previous regulations can and cannot stand, the rulings do not prevent the Trump administration from making other permissible regulatory changes as it deems appropriate, especially as stakeholders have challenged implementation of the law under the previous administration.
Beyond issuing this new set of regulations, the Trump administration also may need to deal with open operational questions and issues, including proposed regulations from the Biden administration that have yet to be finalized and whole provisions of the NSA that are yet to be implemented.[2] All of this means that, if it chooses to act, the Trump administration could decide to make its own imprint on the current NSA operations and policy.
For more information about the NSA, please visit our No Surprises Act Resource Center.

The next wave of ADA website accessibility lawsuits against alcohol suppliers
ARTICLE
The next wave of ADA website accessibility lawsuits against alcohol suppliers
Mar 17, 2025
Read time: 7 min
The increasing popularity of online shopping has made e-commerce businesses – specifically those in the alcohol beverage industry – a frequent target for costly litigation. In lockstep with the continued prevalence of website accessibility cases, plaintiff firms are sending pre-suit demand letters to alcohol suppliers and, in some cases, filing a state or federal court lawsuit. These lawsuits, which are typically filed in California, Florida, or New York, involve claims that a supplier’s website is not accessible to individuals who are blind in violation of Title III of the Americans with Disabilities Act (ADA) and related state laws. In these cases, plaintiffs seek attorneys’ fees, damages (only under state law), and injunctive relief that would require the website to conform with the Web Content Accessibility Guidelines (WCAG) standards, which have been broadly adopted by courts and regulators.
While many e-commerce companies, including alcohol suppliers, have turned to “accessibility widgets” to improve WCAG compliance, these quick-fix solutions are not always what they seem. More than 25% of all website accessibility lawsuits in 2024 (more than 1,000) were brought against businesses that used widgets, with many plaintiffs explicitly citing widget features as alleged obstacles to accessibility. Widget developers have also faced scrutiny. The Federal Trade Commission recently leveled a $1 million fine against one such company for falsely claiming that its widgets “make any website complaint.” Therefore, relying solely on widgets to comply with WCAG standards has proven ineffective and could render e-commerce businesses vulnerable to website accessibility lawsuits.
To prevail on a website accessibility claim, plaintiffs must first show that a defendant is a private entity that owns, leases, or operates a “place of public accommodation.” Courts, however, are split on what it means for a website to be considered a place of public accommodation under Title III of the ADA. While some jurisdictions require a “physical nexus” between the website and a brick-and-mortar store, other jurisdictions have permitted these cases to go forward against a website-only company that does not own or operate any physical retail location. Even so, the “physical nexus” test is applied by a majority of federal courts and was recently adopted by the most active court for ADA website litigation in the country: the US District Court for the Southern District of New York. This development will likely add to an emerging trend of website accessibility plaintiffs resorting to state courts in search of more favorable laws.
In addition to establishing that the supplier’s website is a place of public accommodation, the plaintiff must satisfy certain jurisdictional requirements that will depend on whether products can be purchased directly from the website and whether the supplier ships to the state in which the suit was filed. Leveraging these defenses (among others) will be critical when it comes to either convincing the plaintiff to withdraw the claim, filing a motion to dismiss, or achieving an early resolution on favorable terms.
Due to the rise in these website accessibility lawsuits, we encourage industry members to take a proactive approach by:
- Training personnel on accessibility requirements and WCAG standards.
- Testing their website against WCAG standards (through independent consultants or user testing) and retaining testing documentation to demonstrate that users with disabilities can fully use the website.
- Assessing potential areas of nonconformance with WCAG standards.
- Working with internal and external technical teams to implement accessibility features into the website.
- Developing an accessibility policy that informs users about the company’s accessibility practices.
- Considering including a link to their website accessibility policy on every webpage, including a reporting option that is appropriately routed to address accessibility issues.
- Regularly auditing their website to assess its level of accessibility (particularly after website updates).
- Prioritizing manual audits over “quick fixes,” like accessibility widgets.
- Engaging legal counsel to minimize litigation risk associated with website accessibility issues, including whether the ADA is applicable to the company’s website in light of the current state of the law.

Delaware Proposes Amendments to the DGCL Restricting Stockholder Access to Corporate Records and Loosening Review of Controller Transactions
ARTICLE / CLIENT ALERT
Delaware Proposes Amendments to the DGCL Restricting Stockholder Access to Corporate Records and Loosening Review of Controller Transactions
March 14, 2025
Read time: 7 min
On Feb. 17, 2025, a bipartisan group of Delaware legislators introduced a bill (“SB 21”) proposing a set of significant amendments to the Delaware General Corporation Law (“DGCL”) that, if approved, would dramatically limit stockholders’ ability to access corporate books and records and reduce Delaware courts’ scrutiny of transactions with conflicted controlling stockholders. While ostensibly aimed at increasing clarity and predictability for transactional planners, the proposed amendments likely will create new areas of uncertainty that boards may exploit to avoid accountability to stockholders and remove a potent tool used by activists to uncover board wrongdoings.
Proposed Amendments to DGCL § 220 (Books and Records Demands)
Section 220 of the DGCL grants stockholders the right to inspect corporate books and records and is an important tool for stockholders both in activist campaigns and in investigating wrongdoing by a board. If enacted, SB 21 would significantly curtail this stockholder right by amending Section 220 to, among other things, (1) impose a higher procedural standard for demands, (2) limit documents available through a demand to a specified list of formal corporate records enumerated in Section 220, (3) permit companies to condition the provision of books and records on entry into an confidentiality agreement, and (4) permit a corporation to redact its books and records for relevance.
1. New Procedural Standard for Stockholder Demands Under Section 220
SB 21 proposes that in order for a stockholder to receive and inspect copies of a corporation’s books and records under Section 220, the stockholder must make a demand that meets enumerated procedural requirements. These requirements are that the demand is made in “good faith and for a proper purpose,” “describes with reasonable particularity the stockholder’s purpose and the books and records the stockholder seeks to inspect,” and that the “books and records sought are specifically related to the stockholder’s purpose.” While most demands drafted by sophisticated counsel already meet these requirements, which are largely contained in existing case law, their inclusion in the statutory text will encourage corporate boards to find new bases to refuse to produce documents in response to the demand. The inclusion of the requirement of “good faith,” in particular, appears ripe for abuse, as it ostensibly permits boards to reject a demand simply because the board arbitrarily determines that it was not made in “good faith” by the stockholder, even if the demand otherwise meets all of the procedural requirements of Section 220.
2. Stockholder Demands Under Section 220 Would Be Limited to Certain Formal Records
Under existing Delaware case law, it is possible for stockholders making a demand under Section 220 to obtain both formal corporate board records and informal records and communications, including text messages and e-mails. For stockholders investigating wrongdoing, access to such informal records and communications is a powerful investigatory tool. SB 21 proposes that the documents available to demanding stockholders be limited to an enumerated list of formal board materials and financial statements, including the certificate of incorporation, bylaws, minutes of stockholder meetings, minutes of board or committee meetings, materials provided to the board or any committee, and annual financial statements for three years preceding the date of the stockholder demand.
On March 10, 2025, the Delaware State Bar Association’s Corporation Law Section approved minor revisions to SB 21. Most notably, the revisions included a limited failsafe whereby a court may order production of “other specific records of the corporation,” but only if the stockholder (i) makes a showing of a “compelling need for an inspection of such records to further the stockholder’s proper purpose” and (ii) demonstrates by “clear and convincing evidence” that those records are necessary and essential to further the stockholder’s proper purpose. The “compelling need” standard is significantly harder for a stockholder to meet than the lenient “credible basis” standard courts currently apply. As a result, if this legislation is enacted, stockholders’ Section 220 demands will put less pressure on boards and stockholder investigations of potential wrongdoing will be less effective, as stockholders will lose the ability to obtain emails, text messages, and/or other informal board communications absent an evidentiary showing of compelling circumstances — instead, they will be limited to documents that are typically prepared by counsel and sterilized of pertinent information.
3. Conditioning Production on NDAs
SB 21 would permit corporations to impose restrictions on the confidentiality, use, or distribution of corporate books and records. While Non-Disclosure Agreements (“NDAs”) are customary with respect to stockholders’ Section 220 demands, the proposed amendment opens the door for corporations to both insist on an NDA and require more restrictive NDAs that would require lengthy negotiations amongst counsel, which could allow corporations to push back the timeline for production and increase costs to stockholders.
4. Permitted Redactions of Corporate Books and Records
SB 21 expressly permits corporations to redact portions of any of the books and records it produces to the extent that the redacted material is not specifically related to the purpose of the stockholder’s demand. The proposed amendment does not provide any guidance on how to identify corporate material that is not “specifically related” to the stockholder’s purpose, and will, as a result, likely incentivize corporations to broadly redact otherwise relevant information.
Proposed Amendments to DGCL § 144 – (Controller Transactions)
Consistent with Delaware’s traditional concern for protection of minority investor rights, existing Delaware case law provides for exacting scrutiny by a court for “controller transactions,” i.e., transactions in which a controller of a company receives a benefit not shared generally among all stockholders. Unlike most transactions, which are subject to a deferential business judgment review, controller transactions are subject to “entire fairness” review, in which a court determines whether the transaction was objectively fair to the company, in terms of both process and price. A controller may only avoid entire fairness review if the transaction follows strict procedural safe harbor requirements, including the use of an independent special committee and approval by a majority of the corporation’s minority stockholders, as the Delaware Supreme Court recently re-affirmed in In re Match Group., Inc. Deriv. Litig., 315 A.3d 446 (Del. 2024).
SB 21 effectively overturns Match Group and relaxes the procedural requirements that must be met for a controller transaction to avoid entire fairness review. In addition, SB 21 significantly limits who constitutes a controller and introduces a presumption that a director is not interested in a transaction merely because a board determined such director is independent under stock exchange rules. If enacted, the proposed legislation will reduce Delaware courts’ scrutiny of controlling stockholder transactions and will make it more challenging to bring suit and recover damages suffered by stockholders as a result of a controlling stockholder transaction.
Moving Forward
While this Alert is not an exhaustive list of the amendments proposed to Sections 144 and 220 of the DGCL, it is intended to highlight key provisions should SB 21 be approved and become law, which we expect may happen as early as this month.
Authored by Ele Klein, Randall Adams, Frank Olander, Brandon Gold, Minji Reem, Sean Brownridge and Ashley Cardenas.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

FedEx Defeats Government’s Loper Bright Gambit
ARTICLE
FedEx Defeats Government’s Loper Bright Gambit
Mar 13, 2025
Read time: 4 min
On February 13, 2025, a Tennessee federal district court handed FedEx Corporation its second win in a refund action involving the application of foreign tax credits to what are known as “offset earnings.”[1] Offset earnings are earnings from a taxpayer’s profitable related foreign corporations that are offset by losses from other related foreign corporations. FedEx previously prevailed on the question of whether it was entitled to foreign tax credits related to such earnings.[2] In this most recent ruling, the court rejected the Government’s reliance on a certain regulatory provision called the “Regulatory Haircut Rule”[3] to argue that the amount of FedEx’s claimed refund should be reduced. The case now appears to be set for appeal.
Revisiting the analysis in its first ruling, the court explained the error of the Government’s reliance upon the Regulatory Haircut Rule. In short, the court said that the rule’s application conflicted with the best construction of the governing statutes, primarily Internal Revenue Code (IRC) Sections 960, 965(b)(4), and 965(g). The Government defended its reliance by appealing to Loper Bright’s instruction that courts must respect legitimate delegations of authority to an agency.[4] Citing IRC Section 965(o), which authorized the Secretary of the Treasury to prescribe regulations “as may be necessary or appropriate to carry out the provisions of” Section 965 and to “prevent the avoidance of the purposes” of this section, the Government argued that the Regulatory Haircut Rule furthered the IRC’s broader goal of preventing tax avoidance and that Loper Bright required the court to respect the Secretary’s exercise of his delegated authority.
While acknowledging that legitimate delegations of authority to agencies remain permissible after Loper Bright, the court reminded the Government that an agency does not have the power to regulate in a manner that is inconsistent with the statute, even when a delegation provision grants the agency broad discretionary authority:
Assuming that Congress delegated authority . . . to promulgate regulations implementing section 965 . . . that authority cannot, under Loper Bright, encompass the discretion to promulgate regulations that contravene the “single, best meaning” of section 965, as determined by the courts.[5]
In other words, a statute’s delegation provision should not be interpreted to allow Treasury to eliminate rules that Congress established in other parts of the IRC.
Practice Point:
Referencing Loper Bright’s acknowledgment that Congress may “confer discretionary authority on agencies,”[6] the Government has defended (and likely will continue to defend) its regulations on the theory that its exercises of such authority should be respected. But as Loper Bright reminds us, courts have an independent duty to decide the meaning of statutory delegations. Thus, taxpayers should closely examine whether regulations purportedly derived from a statute’s delegation provision comport with the rest of the statute. Those that do not should be challenged.
[1] FedEx Corp. & Subs. v. United States, No. 2:20-cv-02794 (W.D. Tenn., Feb. 13, 2025)(electronically available here).
[2] FedEx Corp. & Subs v. United States, No. 2:20-cv-02794 (W.D. Tenn., Mar. 31, 2023)(electronically available here).
[3] See Treas. Reg. § 1.965-5(c)(1)(i) (limiting foreign tax credits by the amount of withholding taxes paid to a foreign jurisdiction). The court also rejected the Government’s reliance upon what it called the “Statutory Haircut Rule” based on IRC section 965(g)(1). This discussion focuses on the regulatory counterpart.
[4] See Loper Bright Enters. v. Raimondo, 144 S.Ct. 2244, 2268 (2024).
[5] FedEx, No. 2:20-cv-02794 (W.D. Tenn., Feb. 13, 2025).
[6] Loper Bright, 144 S.Ct. at 2268.

Treasury’s New Outbound Investment Security Program Rule Targeting Investments in China’s Tech Industry and Recent Guidance
ARTICLE / CLIENT ALERT
Treasury’s New Outbound Investment Security Program Rule Targeting Investments in China’s Tech Industry and Recent Guidance
March 13, 2025
Read time: 28 min
Introduction
On Jan. 2, 2025, the US Department of the Treasury’s (“Treasury”) final rule implementing the Outbound Investment Security Program (“OIP”) went into effect, under which US persons are prohibited from engaging in, or are required to provide notification to Treasury of, certain investments involving persons of so-called “Countries of Concern” (currently, the People’s Republic of China, including the Special Administrative Regions of Hong Kong and Macau) that operate in certain technology sectors (“Covered Foreign Persons,” and such transactions involving Covered Foreign Persons, “Covered Transactions”).[1] Specifically, the OIP seeks to minimize the “intangible benefits” from US investment that certain foreign adversaries may exploit to “accelerate and increase the success of the development of sensitive technologies” against US interests.[2] Addressing these concerns, the new restrictions and reporting requirements are focused on investments relating to specified technologies currently consisting of: semiconductors and microelectronics; quantum information technologies; and certain artificial intelligence systems (collectively, “Covered Activities”).[3]
The OIP is now in effect and applies to any transaction that closed or closes after Jan. 2, 2025, with an exception for transactions made after Jan. 2, 2025, pursuant to a binding, uncalled capital commitment entered into before such date.[4] Treasury recently released guidance in the form of frequently-asked-questions (“FAQs”) clarifying certain aspects of these new regulations.[5] The Trump Administration has also signaled that it is considering expanding restrictions on US investment in China, including by modifying the scope of the OIP.[6]
This Alert summarizes the key takeaways from the OIP and related guidance and outlines the scope of the new obligations that the OIP will impose on US persons.
Executive Summary
The OIP imposes new obligations on asset managers and US Persons that make direct or indirect investments in China. Notably, unlike with its sanctions programs that restrict US Persons from dealing with persons and entities designated on the Specially Designated Nationals and Blocked Property List and other sanctions lists, Treasury is not establishing a list of Covered Foreign Persons subject to the requirements of the OIP. US Persons are expected to conduct their own due diligence on investment targets to ensure compliance with the OIP.[7] Additionally, while the OIP has sometimes been referred to as a “reverse CFIUS,”[8] it differs in many aspects, including that compliance is solely the responsibility of US Persons and not their foreign counterparties, and unlike CFIUS, the OIP pre-emptively prohibits certain transactions.
Asset managers should continue to assess the impact of the OIP, and consider whether they need to update relevant risk factors disclosed to investors and anticipate making compliance-related representations to investors. Compliance with the OIP may also require implementing or enhancing due diligence policies and procedures to evaluate (i) the nature of their foreign investments, (ii) the ownership or control of an investment target and (iii) whether any investment targets engage in Covered Activities.
Executive Branch Actions and Federal Lawmaking Initiatives May Further Curtail Investments in China
Outbound investment restrictions targeting China’s military technology industry remain a topic of interest for the Trump Administration and the US Congress, and it is possible that additional Executive Orders or federal legislation augmenting the OIP will be enacted. Most recently, on Feb. 21, 2025, the Trump Administration issued a policy memorandum (“Memorandum”) signaling its intention to increase restrictions on US investments in China under “all necessary legal instruments,” including IEEPA, the Chinese Military-Industrial Complex Companies program administered under Executive Orders 13959 and 14032, as well as potentiatally expanding the scope of the OIP.[9]
The Memorandum does not immediately implement any new restrictions, but directs the Treasury’s Office of Science and Technology Policy to regularly review and update restrictions on investmensts in China in sensitive technology sectors, such as “biotechnology, hypersonics, aerospace, advanced manufacturing, directed energy, and other areas implicated by [China’s] national Military-Civil Fusion Strategy.”[10] The Memorandum also contemplates further review of, and potentially expanded restrictions on, “outbound private equity investments, venture capital investments, greenfield investments, corporate expansions, and investments in publicly traded securities from sources including pension funds, university endowments, and other limited-partner investors.”[11] This Memorandum follows a similarly focused policy statement that was released on Jan. 20, 2025, in which the Trump Administration called for, among other things, a review of the existing OIP to determine whether it “includes sufficient controls to address national security threats” and requiring the Secretary of the Treasury to “make recommendations based upon the findings of [the] review, including potential modifications” to the existing OIP.[12] Pursuant to these two policy statements, the Trump Administration could impose new investment restrictions on US investment in China under multiple authorities, raising the possibility that the OIP could be applied to additional technology sectors and investments types. But as of the date of publication of this Alert, no new investment restrictions have been implemented.
Takeaways
In assessing the implications of the OIP, some key compliance measures for asset managers to undertake include:
- Conducting a risk assessment on investment strategies and portfolios to determine existing or future exposure to potentially Covered Transactions. For example, at this time purchases of publicly traded securities that do not result in acquiring more than minority shareholder protection rights are generally excepted from OIP regulations.
- Evaluating whether to modify disclosures to investors, such as the scope of the asset manager’s investment strategy and any new risk factors arising from the OIP. For example, broad investment strategies may cause investors to seek additional information.
- Updating due diligence procedures to include assessments (such as through questionnaires) of whether investment targets are engaged in Covered Activities and whether they are Covered Foreign Persons, and ensuring such diligence is documented.
- Determining whether any US-managed foreign funds have US investors and whether engaging in potential Covered Transactions may trigger reporting requirements for those investors.
- Anticipating requests for representations regarding Covered Transactions and evaluating how those representations align with compliance obligations under the OIP (which may differ for US and non-US funds) and the fund’s investment strategies, particularly with respect to permissible notifiable transactions.
- Assessing any added compliance burdens relating to filing notifications with Treasury, which are due 30 days from the transaction date.
- Educating compliance and investment personnel about the OIP, and in the case of non-US entities, instituting recusal policies for US Person personnel.
- Monitoring for regulatory changes, additional Executive Orders, and any new guidance from Treasury that may impact the OIP, as well as keeping apprised of legislative efforts similar to the OIP being weighed by Congress.
Below we outline the key provisions of the OIP that asset managers and investors should consider in assessing the impact of the OIP on their investments and any compliance measures they may need to implement.
Key Provisions and Definitions of the OIP
Under the OIP, US Persons (discussed below) are required to determine if they are engaging in a transaction with a potential investment target that is a Covered Foreign Person. Depending on the nature of technology-based activities of a Covered Foreign Person, such transactions may either be prohibited (“Prohibited Transactions”[13]), or may obligate a US Person to notify Treasury of the transactions (“Notifiable Transactions”[14]). US Persons may also have obligations with respect to non-US entities under their direction or control—either to prevent such non-US entities from engaging in certain transactions, or filing notification of a Covered Transaction (discussed below) on their behalf.
US Persons
The OIP applies to all “US Persons,” which means “any United States citizen, lawful permanent resident, entity organized under the laws of the United States or any jurisdiction within the United States, including any foreign branch of any such entity, or any person in the United States.”[15] Non-US asset managers should be aware that the OIP can impact foreign entities that employ US Persons, as well as foreign entities with non-US Person employees who engage in Covered Activities while they are physically located in the US (e.g., during international business travel).[16] Non-US asset managers should consider implementing policies for any US Person personnel to recuse themselves from Covered Transactions and monitor the geographic location of all personnel engaged in Covered Transactions (defined below).
Covered Transactions
The OIP applies to direct or indirect[17] outbound investments by US Persons involving Covered Foreign Persons, including certain acquisitions of equity interests (e.g., mergers and acquisitions, private equity and venture capital) and contingent equity interests, certain debt financing transactions, greenfield and brownfield investments, joint ventures and certain acquisitions of limited partner (“LP”) or LP-equivalent interests by US Persons in non-US Person investment funds.[18] Covered Transactions may either be prohibited or require submitting notification to Treasury, depending on the nature of the specified technologies in which the investment target is involved.
Acquisition of LP or LP-Equivalent Interests in Non-US Pooled Funds
US asset managers should be aware that the acquisition of an LP interest by a US Person in a non-US venture capital fund, private equity fund, fund of fund, or other pooled investment fund (collectively, “Non-US Pooled Fund”) is a Covered Transaction only if (1) the US Person knows or has reason to know at the time of the acquisition that the Non-US Pooled Fund is likely to invest in a person of a Country of Concern who is engaged in a Covered Activity and (2) the Non-US Pooled Fund undertakes a transaction that would be a Covered Transaction if it were undertaken by a US Person.[19]
Controlled Foreign Entities
The OIP also imposes obligations on US Persons with respect to foreign entities that they control (“Controlled Foreign Entities”). A Controlled Foreign Entity means “any entity incorporated in, or otherwise organized under the laws of a country other than the United States of which a U.S. person is a parent.”[20] The OIP further defines “parent” to mean a person that directly or indirectly holds more than 50% of the outstanding voting interest in an entity or of the board of the entity; a general partner, managing member or equivalent of an entity; or an investment adviser (as defined in the Investment Advisers Act of 1940) to any entity that is a pooled investment fund (“Parent”).[21]
Under the OIP, US Persons must take “all reasonable steps to prohibit and prevent” a Controlled Foreign Entity from engaging in a Prohibited Transaction[22] and file a notification to Treasury for any Notifiable Transaction undertaken by a Controlled Foreign Entity no later than 30 calendar days after the completion date of the Notifiable Transaction.[23] The OIP outlines a non-exhaustive list of factors that Treasury will consider in determining whether a US Person took “all reasonable steps to prohibit and prevent” a Controlled Foreign Entity from engaging in a Prohibited Transaction, such as whether agreements to implement training and internal reporting between the US Person Parent and the Controlled Foreign Entity to ensure compliance with the OIP were executed, the implementation, auditing, and testing of appropriate controls, policies and procedures, as well whether such steps were “intended to be effective and … were adequately resourced,” among other factors.[24]
Covered Foreign Persons
A direct or indirect outbound investment by a US Person is not a Covered Transaction unless it involves (or may establish) a Covered Foreign Person. The OIP defines Covered Foreign Persons to include:
- A person of a Country of Concern that is engaged in a Covered Activity;[25]
- A person that is not otherwise a Covered Foreign Person but:
- Has, directly or indirectly, a voting or equity interest in, a board seat (voting or observer) on, or any contractual power to direct or cause the direction of management or policies of, a Covered Foreign Person; and
- More than 50% of the person’s annual revenue, net income, capital expenditure, or operating expenses[26] are attributable to Covered Foreign Persons, either individually or aggregated across all such Covered Foreign Persons from which the person derives or incurs (as applicable) at least $50,000 of the relevant metric;[27]
- With respect to a joint venture transaction that constitutes a Covered Transaction, a person of a Country of Concern that participates in such joint venture.[28]
Covered Activities
The OIP defines Covered Activities to include all Prohibited and Notifiable Transactions as they are defined in the OIP.[29]
Prohibited Transactions
- Semiconductor and Microelectronics Sector. Prohibited Transactions in the semiconductor and microelectronics sector will include Covered Transactions in which the Covered Foreign Person:
- develops or produces design automation software for integrated circuits design or advanced packaging;
- develops or produces equipment for semiconductor fabrication, volume fabrication of integrated circuits, volume advanced packaging or extreme ultraviolet lithography;
- designs or fabricates integrated circuits that meet or exceed specified performance characteristics; and
- packages integrated circuits using advanced packaging techniques.[30]
- Artificial intelligence (“AI”) Systems. Prohibited Transactions in the AI systems sector will include Covered Transactions in which the Covered Foreign Person:
- develops AI systems designed exclusively for or intended to be used for a military, government intelligence or mass surveillance end use; and
- develops AI systems that are trained using a quantity of computing power greater than 10^25 computational operations, or 10^24 computational operations using primarily biological sequence data.[31]
- Quantum Information Technologies Sector. Prohibited Transactions in the quantum information technologies sector will include Covered Transactions in which the Covered Foreign Person:
- develops, installs, sells or produces supercomputers that exceed specified performance and density criteria;
- develops or produces a quantum computer or critical components required to produce a quantum computer;
- develops or produces a quantum sensing platform intended for military, government intelligence or mass surveillance end uses; and
- develops or produces quantum networks or quantum communications systems intended to be used for scaling quantum computing, secure communications or any other application that has a military, government intelligence or mass surveillance end use.[32]
Notifiable Transactions
- Semiconductor and Microelectronics Sector. Notifiable Transactions in the semiconductor and microelectronics sector will include Covered Transactions in which the Covered Foreign Person designs, fabricates and packages certain integrated circuits.[33]
- Artificial Intelligence. Notifiable Transactions in the artificial intelligence sector will include Covered Transactions in which the Covered Foreign Person develops an AI system that does not meet the criteria to make the transaction a Prohibited transaction, but nevertheless is:
- designed to be used for a military end use, government intelligence or mass surveillance end use;
- intended to be used for cybersecurity applications, digital forensic tools, penetration testing tools or the control of robotic systems; or
- trained using computing power greater than 10^23 computational operations.[34]
- Quantum Information Technologies Sector. There are no categories of Notifiable Transactions with respect to the quantum information technology sector.
Excepted Transactions
The OIP establishes conditions under which an otherwise Covered Transaction will not be considered a Notifiable or Prohibited Transaction (“Excepted Transactions”). Subject to certain qualifications, Excepted Transactions include:
- An investment by a US Person in publicly traded securities (as “security” is defined under Section 3(a)(10) of the Securities Exchange Act), denominated in any currency, that trades on a US or non-US securities exchange or “over-the-counter” in any jurisdiction;
- An investment by a US Person in a security issued by a registered investment company (e.g., index fund, mutual fund, exchange-traded fund) or issued by any company that has elected to be a business development company;
- Certain limited partner (“LP”) or equivelant investments by a US Person in a venture capital fund, private equity fund, fund of funds or other pooled investment fund, provided that either (1) the LP or equivalent’s committed capital is not more than $2,000,000, aggregated across any investment and co-investment vehicles of the fund or (2) the LP or equivalent has secured a binding contractual assurance that its capital in the pooled investment fund will not be used to engage in a transaction that would be a Prohibited or Notifiable Transaction if engaged in by a US Person;[35]
- Certain investments by US Persons in derivatives, provided that such investment does not confer the right to acquire equity, any rights associated with equity, or any assets in or of a Covered Foreign Person;[36]
- A US Person’s full buyout of all interests of any person of a country of concern in an entity, such that the entity is not a Covered Foreign Person following the transaction;
- An intracompany transaction between a US Person Parent and its Controlled Foreign Entity that supports new operations that are not Covered Activities or that maintains ongoing operations, including ongoing Covered Activities;
- Fulfillment of a US Person’s binding, uncalled capital commitment entered into prior to the effective date of the OIP (Jan. 2, 2025);
- The acquisition of a voting interest in a Covered Foreign Person upon default or other condition involving a loan, where the loan was made by a lending syndicate and a US Person participated passively in the syndicate;
- The receipt of employment compensation by an individual in the form of stock or stock options, or the exercise of such options; and
- Certain transactions with or involving a non-US Person or entity that have been designated by the Secretary of the Treasury in accordance with certain criteria (yet to be developed) that relate to the foreign country or territory’s own measures to address the national security risk related to a particular outbound investment.[37]
Importantly, even if a transaction falls within the above categories, it is not an Excepted Transaction if the transaction would give a US Person rights with respect to a Covered Foreign Person that are “beyond standard minority shareholder protections.”[38] Additionally, Treasury has also stated that with respect to initial public offerings (“IPOs”), pre-IPO transactions involving the acquisition of equity in a Covered Foreign Person “such as a purchase with the intent to create a market for the security or to resell the security on a secondary market” are Covered Transactions, because the equity interest is not yet publicly traded.[39]
Knowingly Directing an Otherwise Prohibited Transaction
The OIP also prohibits US Persons from “knowingly directing” a transaction by a foreign entity that the US Person knows at the time of the transaction would be prohibited if the transaction were engaged in by a US Person.[40] The OIP clarifies that the “knowingly directing” provision only applies to a US Person that “has authority, individually or as part of a group, to make or substantially participate in decisions on behalf of a non-US Person, and exercises that authority to direct, order, decide upon or approve a transaction” (“Management Personnel”).[41] In its recent FAQs, Treasury explains that a corporate officer who is a member of an investment committee that votes on whether to undertake potential investments has the requisite authority to knowingly direct an otherwise Prohibited Transaction and meets the definition of Management Personnel, while an accountant who conducts financial due diligence on a potential investment at the instruction of corporate management does not.[42] Treasury also notes that the “knowingly directing” provision applies not just to individuals, but also to US entities with such authority.[43]
Recusal Carve-Out
US Persons employed as Management Personnel at foreign entities who fully recuse themselves from the following activities in connection with a Prohibited Transaction will not be determined to have “knowingly directed” that transaction:
- Participating in formal approval and decision-making processes related to the transaction, including making a recommendation;
- Reviewing, editing, commenting on, approving and signing relevant transaction documents; and
- Engaging in negotiations with the investment target or, as applicable, the relevant transaction counterparty.[44]
In order to successfully invoke the recusal carve out, the US Person must “immediately cease” involvement in any of the above activities “prior to” the foreign entity approving and engaging in the Prohibited Transaction.[45] Notably, the “knowingly directing” provision of the OIP captures foreign entities (e.g., non-US asset managers) that employ US Persons as Management Personnel abroad. As such, to avoid violating the OIP, US Person Management Personnel must fully recuse themselves from any involvement in the foreign entity’s decisions relating to such a transaction.[46]
Knowledge Standard
In order for a Covered Transaction to be subject to the OIP, the participating US Person must have knowledge at the time of the transaction that:
- the transaction involves a Covered Foreign Person;
- the transaction will result or is planned to result in the establishment of a Covered Foreign Person (especially applicable to greenfield, brownfield or joint venture investments); or
- the transaction will result or is planned to result[47] in a person of a Country of Concern’s engagement in a Covered Activity (especially applicable to brownfield investments).[48]
For the purposes of the OIP, “knowledge” includes:
- actual knowledge that a fact or circumstance exists or is substantially certain to occur;
- awareness of a high probability of a fact or circumstance’s existence or future occurrence; or
- reason to know of a fact or circumstance’s existence.[49]
Due Diligence
Under the OIP, a US Person is responsible for knowledge they had or could have had through a “reasonable and diligent inquiry” at the time of the transaction.[50] Accordingly, US Persons will need to engage in, and document, due diligence on potential investment targets to ascertain whether the investment is a Covered Transaction.[51] Factors that Treasury will consider in determining whether a reasonable and diligent inquiry was made at the time of the transaction, as outlined in the OIP and reiterated in recent guidance, include:
- questions that the US Person asked of the investment target or other relevant transaction counterparty (e.g., a joint venturer) as of the time of the transaction;
- contractual representations or warranties that the US Person has obtained or attempted to obtain from the investment target or other relevant transaction counterparty with respect to the determination of the transaction’s status as a Covered Transaction and the status of the investment target or other relevant counterparty as a Covered Foreign Person;
- Efforts by the US Person as of the time of the transaction to obtain and consider available non-public information relevant to the determination of a transaction’s status as a Covered Transaction and the status of an investment target or other relevant transaction counterparty as a Covered Foreign Person;
- Available public information, the efforts undertaken by the US Person to obtain and consider such information, and the degree to which other information available to the US Person as of the time of the transaction is consistent or inconsistent with such publicly available information;
- Whether the US Person purposefully avoided learning or seeking relevant information;
- The presence or absence of warning signs, which may include evasive responses or non-responses from an investment target or other relevant transaction counterparty to questions or a refusal to provide information, contractual representations or warranties; and
- The use of available public and commercial databases to identify and verify relevant information of an investment target or other relevant transaction counterparty.[52]
Treasury notes that this is not an exhaustive list, and that its assessment of whether a US Person has undertaken a reasonable and diligent inquiry will ultimately depend on its consideration of the totality of the circumstances.[53] In its recent FAQs, Treasury also acknowledges that information necessary to determine whether a transaction is a Covered Transaction may only be within the possession of an investment target or may be otherwise difficult to obtain.[54] In these cases, obtaining representations and warranties from the investment target relevant to the transaction’s status as a Covered Transaction may, in the absence of other warning signs, provide an indication that a US Person lacked the requisite knowledge to make the OIP applicable. However, Treasury notes that obtaining representations and warranties does not establish a safe harbor.[55] Accordingly, US Persons should be wary of any warning signs indicating that an investment target’s responses to diligence questions are potentially incomplete, inaccurate or untruthful.[56]
Treasury notes in its recent FAQs that while part of a “reasonable and diligent inquiry” includes determining whether an investment target’s subsidiaries are Covered Foreign Persons and whether such subsidiaries “contribute to the investment target’s overall finances in a way that could make the target a [Covered Foreign Person],” this does not create an obligation to conduct a “reasonable and diligent inquiry” into each entity in which the investment target may have an interest.[57] Treasury also anticipates releasing additional guidance on its Outbound Investment Security Program website regarding application of the knowledge standard to the multitude of US foreign investment regimes that exist.[58]
Notification Procedures
Under the OIP, a US Person that engages in a Notifiable Transaction is required to submit an electronic notification to Treasury within 30 calendar days following the completion of the transaction.[59] All notification submissions must include a certification that the notification is in compliance with 31 CFR 850.203.[60] The notification must include certain specified information[61] and be submitted through the Outbound Notification System (ONS) portal[62] in accordance with the electronic filing instructions posted on Treasury’s Outbound Investment Security Program website.[63]
- Recordkeeping. The OIP requires US Persons to maintain a copy of the notification filed and supporting documentation for a period of ten years from the date of the filing.[64] If the US Person does not provide Treasury with the required information, the OIP requires that they (1) provide a “sufficient explanation” for why the information is unavailable or otherwise cannot be obtained and (2) explain their efforts to obtain such information.[65] If such information subsequently becomes available, the US Person must provide this information to Treasury promptly and no later than 30 calendar days following the availability of such information.[66]
- Confidentiality. The OIP generally prohibits Treasury from disclosing to the public information and documentary materials submitted by US Persons in connection with reporting Notifiable Transactions, with certain exceptions for disclosures pursuant to judicial or administrative proceedings and reports made to Congress or a government agency.[67]
- Parties Responsible for Submission. Treasury clarified in a recent FAQ that joint submissions by US persons are not permitted. Each US person participating in a Notifiable Transaction much submit a separate notice and certify to the accuracy of the information submitted.[68]
National Interest Exemption
The Final Rule does not establish a licensing regime for US Persons to engage in Prohibited or Notifiable Transactions. However, the Final Rule permits US Persons to engage in a Prohibited or Notifiable Transaction if they can demonstrate that the Covered Transaction is in the national interest.[69] In determining whether a transaction qualifies under the national interest exemption, Treasury, in consultation with other agencies, will consider, among other factors:
- The transaction’s effect on critical US supply chain needs;
- Domestic production needs in the US for projected national defense requirements;
- US’s technological leadership globally in areas affecting US national security; and
- The impact on US national security if the US Person is prohibited from undertaking the transaction.[70]
Enforcement
A US Person can violate the OIP in any of four ways:
- Taking any action prohibited by the OIP;
- Failing to take any action that the OIP requires within the time frame and manner specified in the OIP;
- Making any materially false or misleading representation, statement or certification, including falsifying, concealing or omitting any material fact when submitting information required by the OIP; or
- Conspiring to violate the OIP or taking any action that evades or avoids, has the purpose of evading or avoiding, causes a violation of, or attempts to violate the OIP.[71]
Violations of the OIP can give rise to the following civil and criminal penalties under the International Emergency Economic Powers Act (“IEEPA”):
- A maximum civil penalty of up to (a) twice the amount of the transaction that is the basis for the violation or (b) approximately $368,000 (adjusted annually for inflation), whichever is greater; and
- For willful violations, a criminal fine of up to $1 million, a prison sentence of up to 20 years, or both.[72]
Consistent with E.O. 14015, the OIP provides that Treasury may take any action authorized by IEEPA to nullify, void, or compel the divestment of a Prohibited Transaction that was entered into after the OIP’s effective date (Jan. 2, 2025).[73]
Authored by Melissa G.R. Goldstein, John Nowak, Hannah Thibideau, Gregoire P. Devaney and Noah A. Wright.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] Final Rule, Provisions Pertaining to US Investments in Certain National Security Technologies and Products in Countries of Concern, 89 Fed. Reg. 90398 (Oct. 28, 2024), available here; see also Treasury, Press Release, Treasury Issues Regulations to Implement Executive Order Addressing US Investments in Certain National Security Technologies and Products in Countries of Concern (Oct. 28, 2024), available here.
[2] White House, Executive Order on Addressing United States Investments in Certain National Security Technologies and Products in Countries of Concern (Aug. 9, 2023) (“E.O. 14105”), available here. The intangible benefits include “enhanced standing and prominence, managerial assistance, investment and talent networks, market access, and enhanced access to financing.” Id.
[3] Final Rule, 89 Fed. Reg. at 90430. Treasury describes these technologies as “pos[ing] a particularly acute national security threat to the United States” because of their significance to the military, intelligence, surveillance or cyber-enabled capabilities of Countries of Concern.
[4] 31 CFR 850.501(d).
[5] See Treasury, Outbound Investment Security Program Frequently Asked Questions (last updated Jan. 17, 2025), available here.
[6] See White House, America First Investment Policy (Feb. 21, 2025), available here.
[7] Outbound Investment Security Program Frequently Asked Questions, FAQ I.10.
[8] The Committee on Foreign Investment in the United States (“CFIUS”) is an interagency body chaired by the Secretary of the Treasury that advises the President on potential national security risks of certain foreign direct investments in the US economy, and has authority to conduct reviews of foreign investments in US businesses (and make recommendations on mitigating any national security risks). 31 CFR 800.101.
[9] White House, America First Investment Policy (Feb. 21, 2025), available here; see also White House, America First Investment Policy Fact Sheet (Feb. 21, 2025), available here.
[10] America First Investment Policy, § 2(j).
[11] Id.
[12] White House, America First Trade Policy (Jan. 20, 2025), available here.
[13] 31 CFR 850.224.
[14] 31 CFR 850.217.
[15] 31 CFR 850.229 (emphasis added).
[16] Outbound Investment Security Program Frequently Asked Questions, FAQ II.2, Example 2.6 and FAQ VI.6, Example 6.1.
[17] “Indirect” Covered Transactions include transactions where a US Person uses an intermediary, such as a special purpose vehicle, for the purpose of acquiring an equity interest in a Covered Foreign Person. Outbound Investment Security Program Frequently Asked Questions, FAQ III.4, Example 4.1.
[18] 31 CFR 850.210.
[19] 31 CFR 850.210(a)(6).
[20] 31 CFR 850.206.
[21] 31 CFR 850.219.
[22] 31 CFR 850.302(a).
[23] 31 CFR 850.404(c). The OIP clarifies that if a US Person submits a notification to Treasury prior to the completion of a transaction, they must update such notification no later than 30 calendar days following the completion date if there are material changes to the information in the original filing. Final Rule, 89 Fed. Reg. at 90437.
[24] 31 CFR 850.302(b); Outbound Investment Security Program Frequently Asked Questions, FAQ V.1.
[25] 31 CFR 850.209(a)(1). A person of a Country of Concern includes nationals and permanent resident of a Country of Concern that are not also US citizens or permanent residents, entities with a principal place of business in, headquartered in, or incorporated in or otherwise organized under the laws of, a country of concern, governments of Countries of Concern and their political subdivisions, and entities in which any of the foregoing holds, individually or in the aggregate, directly or indirectly, at least 50 percent of the outstanding voting interest, voting power of the board, or equity interest. 31 C.F.R. § 850.221
[26] The OIP clarifies that these calculations should be based on an audited financial statement from the most recent year. If an audited financial statement is not available, the most recent unaudited financial statement shall be used instead. If no financial statement is available, an independent appraisal shall be used instead. If an independent appraisal is not available, a good faith estimate should be used instead. 31 CFR 850.209(b)(1).
[27] 31 CFR 850.209(a)(2).
[28] 31 CFR 850.209(a)(3).
[29] 31 CFR 850.208.
[30] 31 CFR 850.224(a) – (e).
[31] 31 CFR 850.224(j), (k).
[32] 31 CFR 850.224(f) – (i).
[33] 31 CFR 850.217(a) – (c).
[34] 31 CFR 850.217(d).
[35] 31 CFR 850.501(a)(1)(iii).
[36] 31 CFR 850.501(a)(1)(iv).
[37] 31 CFR 850.501(g)(1).
[38] 31 CFR 850.501(a)(2). For example, the Treasury describes the ability to nominate and put forward for a vote a slate of directors as a positive right that “goes beyond just protecting the investment of [minority shareholders].” 89 Fed. Reg. at 90443. Accordingly, acquiring a sufficient stake in a publicly traded company that would entitle a US investor to nominate directors is likely not an Excepted Transaction in Treasury’s view.
[39] 89 Fed. Reg. at 90416. Providing an ancillary service for an IPO that does not involve a US Person acquiring equity in the Covered Foreign Person would not be a Covered Transaction. Id.
[40] 31 CFR 850.303(a).
[41] Id.
[42] Outbound Investment Security Program Frequently Asked Questions, FAQ II.2, Examples 2.8 and 2.9.
[43] 89 Fed. Reg. at 90434.
[44] 31 CFR 850.303(b).
[45] Outbound Investment Security Program Frequently Asked Questions, FAQ VI.3.
[46] 89 Fed. Reg. at 90435; see Outbound Investment Security Program Frequently Asked Questions, FAQ VI.3, Example 3.1 (a US Person sitting on the investment committee of a Non-US Pooled Fund must immediately cease from participating in actions or decisions relating to a potential investment target upon obtaining knowledge that the investment would be prohibited if undertaken by a US person).
[47] 31 CFR 850.210(a)(4) (emphasis added); 89 Fed. Reg. at 90422. In the context of brownfield investments, Treasury has made clear that a US Person’s “plans” can be sufficient to establish a Covered Transaction, regardless of whether the transaction actually results in a person of a Country of Concern engaging in a Covered Activity. See Outbound Investment Security Program Frequently Asked Questions, FAQ III.5 (“[T]he Treasury Department nevertheless seeks to address activities intended to result in a person of a country of concern’s engagement in a covered activity, since such a situation is likely to convey intangible benefits from the U.S. person to a covered foreign person.”)
[48] 89 Fed. Reg. at 90405.
[49] 31 CFR 850.216.
[50] 89 Fed. Reg. at 90404 (emphasis added).
[51] Treasury clarified in a recent FAQ that US Persons who outsource their pre-transaction diligence to non-US third parties “must evaluate whether the diligence conducted by the non-US Person entity is sufficient to meet the standard of a ‘reasonable and diligent inquiry.’” See Outbound Investment Security Program Frequently Asked Questions, FAQ VI.2.
[52] 31 CFR 850.104(c); Outbound Investment Security Program Frequently Asked Questions, FAQ V.2.
[53] 31 CFR 850.104(d); Outbound Investment Security Program Frequently Asked Questions, FAQ V.2.
[54] Outbound Investment Security Program Frequently Asked Questions, FAQ V.3.
[55] Id.
[56] Id. at FAQ V.4.
[57] Id.
[58] Treasury, Outbound Investment Security Program (last updated Jan. 17, 2025), available here.
[59] 31 CFR 850.404(c); Treasury, Form Template for § 850.401 Notifications (Undertaking a Notifiable Transaction) (Jan. 17, 2025), available here; Treasury, Form Template for § 850.402 Notifications (Notification of Actions of a Controlled Foreign Entity) (Jan. 17, 2025), available here.
[60] 31 CFR 850.404(a), (b); Treasury, Form Template for § 850.203 Certification (Jan. 2, 2025), available here.
[61] For the complete list of required notification content, please refer to 31 CFR 850.405(b).
[62] Treasury, Outbound Notification System (ONS) Portal (Jan. 2, 2025), available here.
[63] Treasury, ONS User Guide (Jan. 2 2025), available here.
[64] 31 CFR 850.405(c).
[65] 31 CFR 850.405(d).
[66] 31 CFR 850.403; Treasury, Form Template for § 850.403 Notifications (Notification of Post-Transaction Knowledge) (Jan. 17 2025), available here.
[67] 31 CFR 850.801.
[68] Outbound Investment Security Program Frequently Asked Questions, FAQ IX.1.
[69] 31 CFR 850.502.
[70] 31 CFR 850.502(b).
[71] 31 CFR 850.601-604.
[72] 31 CFR 850.701.
[73] 31 CFR 850.703.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

FDA, OHRP Issue Joint Guidance on Collection of Tissue Biopsies in Clinical Trials
ARTICLE / CLIENT ALERT
FDA, OHRP Issue Joint Guidance on Collection of Tissue Biopsies in Clinical Trials
March 12, 2025
Read time: 6 min
On January 6, 2025, the US Food and Drug Administration (FDA) and the US Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) released a joint draft guidance document: Considerations for Including Tissue Biopsies in Clinical Trials. The guidance provides recommendations to industry, institutions, and institutional review boards (IRBs) regarding tissue biopsies performed as part of FDA-regulated clinical investigations or clinical trials conducted or supported by HHS. These recommendations help distinguish necessary and unnecessary biopsies that are included in investigational medical product trials or other study interventions and will inform study design and the structure of informed consents.
The guidance specifically addresses the inclusion of tissue biopsies in clinical trial protocols for both adults and children. The draft guidance applies to FDA-regulated clinical investigations and HHS-supported or -conducted nonexempt human subjects research that is a “clinical trial” as defined in the Federal Policy for the Protection of Human Subjects. The draft guidance does not apply to the acquisition of fluid samples such as blood, urine, or saliva or tissue biopsies needed for routine clinical care.
FDA and OHRP acknowledge that biopsies inherently include varying degrees of risk and that in some cases requiring biopsies may unnecessarily increase risk, create undue burden for trial participants, limit access to trials, and even discourage participation. The draft joint guidance aims to clarify:
- When a biopsy is necessary for a study such that it is appropriate for consent to the biopsy to be a condition for study participation
- When a biopsy should be considered optional.
The guidance suggests several factors for sponsors, investigators, institutions, and IRBs to consider when evaluating the necessity of biopsies during clinical trials. These factors include the purpose of the biopsies, the reasons for their inclusion in the study, and the risks posed by the biopsies. The guidance also suggests that for biopsies that pose higher risks, alternative methods of intervention should be evaluated and a strong scientific justification should be provided.
Mandatory Biopsies
The guidance states that mandatory biopsies may be justified when the information cannot be obtained from existing pathology specimens or other less invasive means, and the information is necessary to, for example:
- Identify participants who may benefit from the investigational product
- Exclude participants at risk of side effects or toxicities
- Determine participants unlikely to benefit from the investigational product
- Evaluate primary or key endpoints of the trial
- Assess treatment response
- Support performance diagnostic testing with a high validity “truth standard.”
Optional Biopsies
Biopsies should be optional when the information obtained from them is used solely for non-key secondary or exploratory endpoints. Additionally, if the purpose of the biopsy is to collect specimens for future unspecified research, the biopsy should not be mandatory. This approach helps to minimize unnecessary risks and burdens on trial participants, ensuring that only essential biopsies are required.
General Guidelines
The draft guidance also outlines considerations and recommendations for designing clinical trials that include one or more biopsies. Sponsors should clearly state the rationale and scientific justification for the inclusion of each biopsy in the study protocol. The draft guidance emphasizes that risks should be minimized for both required and optional biopsies, and that participants for whom a biopsy presents an unacceptable level of risk should be excluded from the study. Sponsors are also encouraged to specify how a biopsy will be analyzed when the biopsy information is used in endpoint analyses.
A participant’s informed consent, which is required for all biopsies, should be obtained under conditions that minimize coercion or undue influence, and that specify foreseeable risks or discomforts. Investigators also must communicate the necessity of the procedure to healthcare providers performing the biopsy and ensure that these providers minimize risks to the extent possible for the trial participants. Participants can withdraw consent for a biopsy at any time during a clinical trial, although doing so when a biopsy is required may affect the participant’s continuation in the trial. According to the draft guidance, however, declining one or more optional biopsies should not negatively impact a participant’s trial enrollment, participation in other aspects of the trial, care the participant receives during the trial, or other study considerations.
Special Consideration for Children
The guidance emphasizes additional safeguards for clinical trials involving children. The draft guidance suggests that biopsies conducted solely for research purposes should present minimal risk or a minor increase over minimal risk to the child, or the biopsy should offer the prospect of a direct benefit to the child. For example, a biopsy that identifies whether a child would likely have a favorable response to an investigational medical product offers the prospect of a direct benefit. If a biopsy offers the child a direct benefit, the biopsy’s risks must be reasonably justified in relation to the anticipated benefit. If a biopsy is not for a child’s direct benefit and is not considered minimal risk, the biopsy must be likely to yield vital knowledge about the child’s condition. In addition to the required parental consent, the draft guidance encourages obtaining a child’s assent to the biopsy where appropriate given the child’s age, maturity, and psychological state.
Key Takeaways
This draft guidance is particularly useful for clinical trial sponsors, investigators, institutions, and IRBs involved in planning and conducting clinical trials. The guidance provides a useful framework for determining when biopsies are necessary in clinical trials and helps to balance the need for biopsy data with the safety and comfort of trial participants. It underscores the need for clear communication in trial protocols and informed consent documents, helping participants understand when biopsies are optional and what risks they involve.
For more information about the draft guidance and its potential impact on clinical research, contact one of the authors of this article or any other member of McDermott’s Health & Life Sciences Practice Group.

The English Arbitration Act 2025: Developments in the Lex Arbitri of a Leading Jurisdiction for International Arbitration
ARTICLE / CLIENT ALERT
The English Arbitration Act 2025: Developments in the Lex Arbitri of a Leading Jurisdiction for International Arbitration
March 12, 2025
Read time: 9 min
On 24 February 2025, the Arbitration Act 2025 entered into force, introducing various amendments to the Arbitration Act 1996. The amendments introduced do not effectuate a large-scale reform of the arbitration law of England and Wales. That is because they did not need to; the English Arbitration Act 1996 has long-governed international arbitrations seated in England and Wales in an effective, expeditious and arbitration-friendly manner. • Instead, the Arbitration Act 1996 has been clarified and refined in certain respects with the goal of enhancing the attractiveness of England and Wales – and particularly London – as a seat for international arbitration.
This article highlights some of practical benefits that arbitration users can expect to receive from the amended Arbitration Act 1996.
Will the Arbitration Act 1996 in Its Original Guise Continue to Apply?
Yes. The Arbitration Act 2025 (AA 2025) does not render the Arbitration Act 1996 (AA 1996) obsolete. To the contrary, the AA 1996 in its original guise will continue to govern arbitration proceedings seated in England and Wales that were commenced before the AA 2025 entered into force.
This remains a positive thing for existing international arbitrations seated in England and Wales. The AA 1996 embodies the jurisdiction’s arbitration-friendly statutory policy. It is expressly founded on the notion of party autonomy, striving to honour how parties agree to have their disputes resolved. It also limits the bases for challenging arbitral awards and restricts the extent to which the English court can intervene in arbitral proceedings. That is why the AA 2025 did not set out to demolish and rebuild the legal framework of the AA 1996 entirely but only to ‘fine tune’ it.
When Do the Amendments Introduced by the Arbitration Act 2025 Start to Apply?
Subject to any transitional arrangements put in place by the Secretary of State, the AA 2025’s amendments will start to apply to all arbitral proceedings seated in England and Wales that are commenced after its entry into force. It does not matter if the arbitration agreement giving rise to those proceedings is dated earlier; in terms of the AA 2025’s temporal application what matters is the date on which the arbitral proceedings themselves are commenced. This means that clients’ pre-existing contractual relationships, as well as disputes that are already crystallised but have not yet been submitted to arbitration, can benefit from the amendments introduced by the AA 2025.
What Particularly Noteworthy Amendments Does the Arbitration Act 2025 Introduce?
1. Settling the debate on the law applicable to arbitration agreements
The AA 2025 introduces a new statutory rule providing that, in the absence of an express choice of law clause specifically applicable to the agreement to arbitrate recorded in the arbitration clause of the parties’ main agreement, the arbitration agreement shall be governed by the law of the arbitral seat, not by the applicable substantive law governing the parties’ substantive rights and obligations in the main agreement. Put differently, if parties wish to have disputes arising out of or in connection with the main agreement referred to arbitration seated in London, and, at the same time, wish their arbitration agreement to be governed by a law other than English law, they will now have to make that choice expressly, whether or not English law is the substantive law applicable to the main agreement. Absent that choice, English law would be the default law governing the arbitration agreement by virtue of London being the agreed arbitral seat. This new rule is a corollary of one of the cornerstones of international arbitration, namely that the agreement to arbitrate recorded in an arbitration clause is separate and independent from the main agreement that contains it. This has important practical implications for arbitration users. It is indeed the law governing the arbitration agreement which, in principle, will determine, among other things: (i) how the parties’ agreement to arbitrate is to be construed, (ii) whether a non-signatory party may be joined in proceedings instituted under that arbitration agreement, (iii) whether a particular dispute is arbitrable, and (iv) what disputes might fall within the scope of the arbitration agreement.
2. Imposing a duty of impartiality on arbitrators
The AA 2025 introduces a new statutory rule codifying the English common law duty of impartiality on arbitrators. The new rule imposes this duty on arbitrators prior to their appointment; for example, when they are first approached in connection with their possible appointment. It also imposes this duty on arbitrators after their appointment, such that it is an ongoing duty that persists until they become functus officio. To fulfil their duty in both respects, arbitrators (including prospective arbitrators) must disclose circumstances that might reasonably give rise to justifiable doubts as their impartiality in relation to the arbitration. Importantly, that duty extends to circumstances of which the arbitrator (or prospective arbitrator) is aware and of which they ought reasonably to be aware. The new rule does not set out what needs to be disclosed and in what circumstances. However, it was drafted intentionally in that way to reflect that practices differ across industries and jurisdictions. This is another welcome amendment that reinforces international arbitration as a dispute resolution mechanism for ensuring a level playing field between disputing parties.
3. Extending the immunity of arbitrators
Arbitrators already enjoyed immunity from suit under the AA 1996. Amendments introduced by the AA 2025 now extend that immunity so that an arbitrator will not be liable for any actions or omissions in the (purported) discharge of their duties unless they acted in bad faith. Similarly, an arbitrator will not be liable for the costs of a party’s application to court to be removed unless the arbitrator has acted in bad faith. These are beneficial amendments because, by mitigating their exposure to collateral challenges by parties who are unhappy with their rulings, arbitrators can continue to make robust and impartial decisions.
4. Protecting the competence of arbitral tribunals to rule on their own jurisdiction
It is a fundamental principle of internation arbitration worldwide that an arbitral tribunal has jurisdiction to rule on its own jurisdiction (commonly referred to as the ‘competence-competence’ principle). The AA 2025 reinforces that principle by limiting the intervention of the English court into questions concerning an arbitral tribunal’s jurisdiction in two main ways. First, the AA 2025 precludes a disputing party from applying to the English court to decide whether an arbitral tribunal has jurisdiction by way of a preliminary point of law in circumstances where the arbitral tribunal itself has already decided the same jurisdictional question. Second, the AA 2025 empowers the Civil Procedure Rules Committee to draft new Civil Procedure Rules that preclude the English court from considering an application to challenge an arbitral tribunal’s award based on its (alleged) lack of jurisdiction in circumstances where that challenge is based on the same legal grounds and/or evidence that were raised (or could have been raised) before the arbitral tribunal—in other words, there can be no ‘retrial’ before the English court on jurisdictional issues already decided by the arbitral tribunal unless it is necessary in the interests of justice. These amendments are particularly attractive for guarding against parties enjoying a second bite of the same apple, while still granting the English court the final say on de novo jurisdictional issues.
5. Empowering arbitral tribunals to dismiss claims and defences summarily
While most institutional arbitration rules already allow arbitral tribunals to dismiss manifestly unmeritorious claims summarily to avoid wasting time and costs in protracted arbitral proceedings, the AA 1996—like most national arbitration laws—made no express provision for this. Arbitrators were, therefore, sometimes reluctant to take advantage of their powers of summary disposal under institutional rules for fear of having their decisions challenged before the court at the arbitral seat on due process grounds. However, the AA 2025 has now introduced a new statutory rule empowering arbitral tribunals to dispose of claims or defences that lack any real prospect of success at an early stage in the arbitration. This should improve the efficiency of international arbitrations seated in England and Wales (including ad hoc arbitration proceedings, for which no set of institutional rules envisaging the summary disposition of claims or defence exists), particularly to prevent parties incurring unnecessary time and costs engaging with spurious claims or defences. That said, arbitral tribunals must take care to ensure that summary disposal does not become a routine step invoked by one party simply to delay the proceedings.
6. Extending the English court’s powers to support arbitral proceedings
The English court has long endeavoured to support arbitrations seated in England and, in certain specific circumstances, even outside England. This support is now enhanced by two amendments introduced by the AA 2025. First, in laying to rest much legal uncertainty, the AA 2025 clarifies that the English court can exercise its powers to support arbitral proceedings over third parties, even if they are not a party the arbitration. This includes the court’s powers relating to the taking and preservation of evidence, property orders, sale of goods, interim injunctions and appointing receivers. Second, it empowers emergency arbitrators appointed under the rules that the parties have selected in the resolution of their disputes to make a peremptory order, and, in cases of non-compliance, ensures that the order can be enforced by the English court (in the same way as the English court would enforce orders of ‘normal’, i.e., non-emergency, arbitral tribunals).
Conclusion
As is clear, the AA 2025 introduces several noteworthy amendments to the AA 1996, particularly in strengthening the powers of arbitrators and emergency arbitrators, enhancing support for arbitral proceedings seated within the jurisdiction of the courts of England and Wales, and updating statute in line with developments in international arbitral practice and English common law. That said, certain proposed amendments to the AA 1996 did not make the final cut of the AA 2025. For example, despite the Law Commission having advocated hard for a prohibition of discrimination in the appointment of arbitrators, the AA 2025 features no such provision (for instance, one requiring that an arbitrator have a nationality different from the parties).
Nevertheless, the amendments that have been introduced by the AA 2025 present strategic reforms to the AA 1996 that posit England and Wales as one of the most robust, arbitration-friendly jurisdictions worldwide. It is also good news for arbitration users that we should see the benefits of these amendments imminently, with the UK government having indicated that they will be enacted through regulations as soon as possible.

HHS OCR Investigates Medical Schools and Hospitals for Race- or Sex-Based Programs
CLIENT ALERT / US POLICY
HHS OCR Investigates Medical Schools and Hospitals for Race- or Sex-Based Programs
March 11, 2025
Read time: 4 min
On March 7, 2025, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) announced that it would begin investigating four medical schools and hospitals pursuant to President Donald Trump’s Executive Order (EO) 14173, Ending Illegal Discrimination and Restoring Merit-Based Opportunity. According to the press release, OCR received reports of violations of Title VI of the Civil Rights Act of 1964 and Section 1557 of the Affordable Care Act, alleging that the medical schools and hospitals offered medical education, training, or scholarship programs for prospective practitioners based on race, color, national origin, or sex.
Title VI prohibits discrimination based on race, color, or national origin, and governs programs and activities that receive federal financial assistance. Similarly, Section 1557 of the Affordable Care Act prohibits discrimination based on race, color, national origin, sex, age, or disability in healthcare programs and activities. The final rule for Section 1557, issued on July 5, 2024, extends its application to any health program or activity that receives funding from HHS, including hospitals accepting Medicare or doctors who receive Medicaid payments. Individuals may file complaints with the DOJ or file suit in federal court for alleged violations of Title VI.
There have been other recent challenges to minority healthcare initiatives under Title VI and Section 1557. In 2024, the Wisconsin Institute for Law and Liberty (WILL), a nonprofit organization whose stated mission is to advance conservative principles through litigation, education and public discourse, filed a complaint on behalf of Do No Harm with the OCR under Title VI and Section 1557 against an academic medical center claiming that the academic medical center’s minority stroke program and clinic were examples of racial discrimination because they specifically targeted Black and Latino populations. Notwithstanding the justification that these programs helped understand and address the increased risk of stroke for those populations and racial health disparities, Do No Harm claimed that the non-Black and Latino members of the community were harmed by the center’s focus on racial minorities when “stroke and diabetes are leading causes of death in the United States” and “mental health conditions plague more than one in five adults.” Do No Harm claimed the programs were improperly “infected” with a “racially motivated focus.” At the time of this alert, OCR’s investigation into this complaint is ongoing.
We expect these investigations to increase. The March 7, 2025, investigation announcement encourages those who “believe that you or someone else has been discriminated against” on the basis of protected characteristics to file a complaint with OCR. This coincides with President Trump’s EOs directing federal agency heads to identify other companies and educational institutions who this administration deems are operating unlawful programs focused on racial and gender minorities. However, this potential increase in investigations is not without legal uncertainty, especially given the varying state-level policies leading to inconsistent approaches across different medical schools, hospital and health systems, and regions.
For many medical schools and hospitals, the evaluation or outright removal of diversity, equity, and inclusion or health equity language and criteria from mission statements and public-facing materials from various programs and initiatives signals a significant departure from previous commitments to diversity and inclusion, potentially affecting how these institutions are perceived by staff and the communities they serve. As scrutiny increases, educational institutions and hospitals and health systems should carefully assess the eligibility criteria for their programs and initiatives based on race, sex, national origin, or color, as programs that are open to all may be less susceptible to scrutiny. Further, institutions should review marketing of their programs and initiatives to the public to ensure they are not making statements or representations implying that race or sex is a criterion for acceptance or participation.
